Placing

RNS Number : 3512C

WideCells Group PLC

12 April 2017

 

12 April 2017

WideCells Group PLC ('WideCells Group' or 'the Company')

                    Completion of a £648,696 fundraising to expand the Company's three divisions

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, is pleased to announce that it has raised gross proceeds of £648,696 by way of a private placing (the 'Placing').

Use of Proceeds

WideCells is focused on becoming a leading provider of services which make stem cell treatment affordable and accessible to families around the world.  With the Placing proceeds now raised, the Company is positioned to execute on a range of additional opportunities it has identified since listing in July 2016 to rapidly accelerate the roll out of its three stem cell services divisions, CellPlan, WideCells and WideAcademy, and further its penetration of this growing market.  With this in mind, in order to streamline and enhance its operations, a portion of the funds will be used to develop a Client Relationship Management ('CRM') System for use across all three of its divisions.  In addition to this the funds will be used as follows:

CellPlan

The demand for the Company's first-of-its-kind stem cell insurance product, CellPlan, is ahead of management expectations.  Therefore, the Company plans to optimise its e-commerce platform which will facilitate its geographic expansion and support the progression of numerous campaigns simultaneously.  The CellPlan Excel Membership Programme, the Company's quality assessment programme, has received applications from numerous cord blood banks in respect to offering CellPlan to their clients.  The applications have been received from companies located across multiple continents which together store over 175,000 stem cell samples.  In line with the Company's focus on partnering with 'best-in-class' facilities, the Company is currently conducting quality assessments to evaluate the eligibility of each cord blood bank that have either signed a Letter of Intent or have submitted their CellPlan Excel Application Forms to CellPlan.

WideCells

The Company's first stem cell storage facility, the Institute of Stem Cell Technology at the University of Manchester Innovation Centre ('UMIC'), remains on track to become operational in Q2 2017.  As highlighted in the announcement dated 30 November 2016, WideCells has been appointed to undertake contract research at the facility and on investigation, the Board has identified that this represents an additional strong market opportunity. Therefore the Company has applied for a research licence. With this in mind, ~£150,000 will be used to rent additional administrative office space at the UMIC and to optimise its Quality Management System in order to capitalise upon this and drive additional revenues.  

WideAcademy

A portion of the funds raised will support the new initiatives developed by Alan Greenberg, the Former Director of Education at Apple, who recently joined the Company as Non-Executive Director and Vice President of WideAcademy.  WideAcademy is focused on becoming a thought leader in stem cell technology and accordingly the Company aims to galvanise Mr. Greenberg's excellent digital experience and network to establish itself as a high-profile resource for both healthcare professionals and families alike.  It aims to achieve this goal by establishing collaborations with leading multinational technology companies and reputed educational institutions and developing a mobile App which can deliver and distribute high quality and trustworthy information about this cutting edge and innovative industry.  The funds will also contribute towards the appointment of key personnel to support the implementation of these new initiatives.  Previous to Alan's appointment, the Company developed a syllabus of short courses for professionals alongside the University of Westminster.  WideCells will make a further announcement on its strategy and key developments in relation to this, in due course. 

WideCells Group CEO, João Andrade, said, "WideCells is focused on becoming a leading provider of stem cell services globally, and these funds will enable us to drive a range of new initiatives which have been identified by our world-class Board since listing to expedite our market penetration and establish new revenue streams.  These are additional to the opportunities which were outlined in our prospectus, which are on track to deliver cash flow in H2 2017, demonstrating the strength of the opportunity which lies within this exciting and growing market.  Positively, the Board's participation in the Placing aligns them closely with our shareholder base and incentivises them to successfully execute on these new plans.

"The funds will be split across all three of our unique business divisions.  CellPlan is receiving a fantastic reception and the level of interest from storage facilities is beyond our original expectations.  In terms of WideCells, thanks to a contract to conduct research at our Institute of Stem Cell Technology, we are already generating revenues ahead of our original plans.  Therefore, we have allocated some funds to capitalise and grow our presence in this market.  Finally, Alan Greenberg has presented us with an opportunity to establish WideAcademy as a go-to digital resource for healthcare professionals and families who want to find out more about the US$100 billion stem cell industry.  We plan to build an App, and collaborate with leading digital influencers who share our vision of making the cutting edge more accessible.  I hope investors share in our excitement for the coming months. I look forward to providing updates regularly as we focus on creating a global company with multiple revenue streams."

The Placing

The Placing has raised gross proceeds of £648,696 by the issue of 5,405,806 new ordinary shares of £0.0025 each in the share capital of the Company (the 'Placing Shares') to new and existing shareholders and Directors of the Company, at a price of 12 pence per Placing Share (the 'Placing Price'), conditional only on Admission (as defined below).

Applications have been made for admission of the Placing Shares to listing on the Standard segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc ('Admission').  Admission is expected to take place on 28 April 2017.

The Placing Shares will rank pari passu in all respects with the existing ordinary shares in the share capital of the Company (including as to the right to receive dividends (and other distributions, if any) declared, made or paid by the Company after the date of issue of the Placing Shares).

Directors' participation in the Placing

Details of the directors' participation in the Placing are set out below:

Director	Number of Placing Shares subscribed for	Price per Placing Share	Number of shares held following the issue of the Placing Shares	Shareholding following the issue of the Placing Shares
João Andrade	20,000	Placing Price	8,040,000	13.5%
David Bridgland	80,000	Placing Price	332,552	0.6%
Lopes Gil	15,000	Placing Price	8,035,000	13.5%
Graham Hine	40,000	Placing Price	3,238,698	5.4%
Marilyn Orcharton	15,000	Placing Price	150,952	0.3%

The notification set out below (made in accordance with the requirements of the Market Abuse Regulation (EU) 596/2014 ('MAR')) provides further detail of the directors' participation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Names	1. João Andrade - Chief Executive Officer 2. David Bridgland - Chief Financial Officer 3. Lopes Gil - Chief Operating Officer 4. Graham Hine - Chairman 5. Marilyn Orcharton - Non-Executive Director
2	Reason for the notification
a)	Position/status	Directors of the Company
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	WideCells Group PLC
b)	LEI	n/a
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.0025 each
b)	Identification code	GB00BD060S65
c)	Nature of the transaction	Placing
d)	Price(s) and volume(s)	Name Price(s) Volume(s) João Andrade David Bridgland Lopes Gil Graham Hine Marilyn Orcharton 12p 12p 12p 12p 12p 20,000 80,000 15,000 40,000 15,000
d)	Aggregated information  - Aggregated volume - Price	170,000 £20,400 (170,000 new ordinary shares at 12 pence per new ordinary share)
e)	Date of the transaction	11 April 2017
f)	Place of the transaction	Outside a trading venue

Total voting rights

Following the issue of the Placing Shares the Company's total issued share capital will consist of 59,463,867 ordinary shares of £0.0025 each.  As each ordinary share carries one vote the total number of voting rights attached to the ordinary shares in the Company is 59,463,867.  

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ordinary shares in the Company in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

**ENDS**

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group	CEO - João Andrade	Tel:  [phone]
Smaller Company Capital Ltd	Broker - Jeremy Woodgate & Rupert Williams	Tel: [phone]
Shard Capital Partners LLP	Broker - Damon Heath & Erik Woolgar	Tel: [phone]
St Brides Partners Ltd	PR - Elisabeth Cowell & Charlotte Page	Tel: [phone]

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.  With this in mind, it has created three divisions:

·     CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

·     WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising on stem cell storage.

·     WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

·     Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of this.

·     Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

·     82 illnesses can currently be treated using stem cell procedures.

·     Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands.

This announcement contains inside information for the purposes of Article 7 of MAR.

 

END

 

 

MSCBBGDSIUBBGRD